Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
Last trade$6.09
Day change+$0.01 (+0.16%)
Day range$5.92 – $6.43
Volume112,587
Market cap$185M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$185.46M
Price / earnings
—
Price / book
-1.42×
Price / sales
180.93×
EV / sales
109.95×
EV / EBITDA
-1.13×
Profitability
Earnings per share
-$4.25
Return on assets
-44.01%
Return on equity
99.27%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-0.38×
Current ratio
8.38×
Quick ratio
8.38×
Cash ratio
7.83×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$89.89M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for RNAC, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$78K
$947K
$452K
$298K
$1.1M
—
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$78K
$947K
$452K
$298K
$1.1M
—
Selling, general and administrative
$9.38M
$8.72M
$7.11M
$8.2M
$7.72M
$7.24M
$8.32M
—
Research and development
$15.62M
$20.43M
$19.46M
$14.69M
$13.8M
$14.87M
$14.67M
—
Total operating expenses
$25M
$29.16M
$26.58M
$79.59M
$21.52M
$22.11M
$22.99M
—
Operating income
-$25M
-$29.16M
-$26.5M
-$78.64M
-$21.07M
-$21.81M
-$21.89M
—
Interest expense
-$1.99M
-$852K
$0
$0
$0
$0
$0
—
Income before taxes
-$11.47M
$15.77M
-$39.18M
-$101.77M
-$35.9M
$15.89M
-$17.71M
—
Income taxes
$0
$0
$0
-$9.19M
$0
$0
$0
—
Net income
-$11.47M
$15.77M
-$39.18M
-$92.58M
-$35.9M
$15.89M
-$17.71M
—
Net income attributable to common shareholders
-$11.47M
$13.72M
-$39.18M
-$92.58M
-$35.9M
$13.26M
-$17.71M
—
EBITDA
-$24.22M
-$28.38M
-$25.88M
-$21.33M
-$20.46M
-$21.22M
-$20.73M
$486K
Basic earnings per share
-$0.38
$0.47
-$1.46
-$3.56
-$1.38
$0.51
-$0.68
—
Diluted earnings per share
-$0.38
$0.46
-$1.46
-$3.62
-$1.38
$0.50
-$0.68
—
Recent news
Company coverage with links to the original publishers.
Cartesian Therapeutics (RNAC) has formed a hammer chart pattern after a 15.7% weekly decline, suggesting potential trend reversal. The stock has a Zacks Rank #2 (Buy) rating supported by a 30.5% increase in consensus EPS estimates over the last 30 days, indicating analyst optimism about future earnings.
DelveInsight released a comprehensive competitive landscape report on BCMA-targeted therapies, analyzing 100+ pipeline drugs across 80+ companies. The report highlights recent clinical advances including Pfizer's positive Phase III results for ELREXFIO, AbbVie's BLA submission for etentamig, and Gilead's $7.8 billion acquisition of Arcellx to gain control of anito-cel. Key challenges include treatment resistance, relapse, and manufacturing complexity, while the pipeline focuses on improving durability, safety, and accessibility through next-generation approaches.
Over 25 pharmaceutical companies are advancing 30+ pipeline drugs for myasthenia gravis treatment, with approximately 5+ therapies in late-stage development. Key players including Immunovant, Cartesian Therapeutics, Novartis, and others are developing promising therapies using novel mechanisms of action such as IgG degraders and complement inhibitors. Recent developments include positive Phase III trial results and regulatory approvals for multiple candidates.
Cartesian Therapeutics secured up to $150 million in non-dilutive financing from K2 HealthVentures, with an initial $50 million tranche extending cash runway into 2028. The company expects Phase 3 AURORA trial topline data for Descartes-08 in myasthenia gravis in Q1 2027, with BLA filing planned for mid-2027. Additional clinical data from Phase 2 TRITON (myositis) and Phase 1/2 HELIOS (juvenile dermatomyositis) trials are expected in H1 2027.
The myasthenia gravis market is projected to grow from USD 6 billion in 2025 to over USD 16 billion by 2036, driven by rising diagnosed prevalence, improved diagnostics, and an expanding pipeline of targeted biologic therapies including FcRn inhibitors, complement inhibitors, and CAR-T cell therapies. The market is currently led by argenx and UCB, with numerous emerging candidates in late-stage development expected to significantly accelerate growth.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.